Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition

The AURELIA trial demonstrated that adding Bevacizumab to chemotherapy significantly improved progression-free survival (PFS) for platinum resistant recurrent ovarian cancer. Recently, immunotherapy also presented potential anti-tumor effects in several malignant solid tumors. This study aimed to in...

Full description

Bibliographic Details
Main Authors: Lei Zhang, Ying Chen, Fangxuan Li, Lewen Bao, Wenxin Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Immunology
Subjects:
PD-L1
Atezolizumab
angiogenesis
Bevacizumab
ovarian cancer
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.00867/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.00867/full

Similar Items